Komori
Disclosure4556KAINOS Laboratories,Inc.Pharmaceuticals

Notice of the Delisting of Our Shares

As the proposal for a share consolidation was approved at the extraordinary general meeting of shareholders, the Company's common shares will be delisted from the Tokyo Stock Exchange Standard Market effective 11 June 2026.

Worth reading
64In focus
Scored from 5 of 6 sections
Direction
Deterioration
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

Decision and Details

Extraordinary General Meeting of Shareholders

Delisting of our shares

Decision25 May 2026
Implementation11 June 2026 (scheduled; delisting from the Tokyo Stock Exchange Standard Market)
Going forwardThe shares will be delisted from the Tokyo Stock Exchange Standard Market effective 11 June 2026.
Reason

The proposal concerning the share consolidation was approved as originally proposed, resulting in the shares meeting the delisting criteria stipulated in the Tokyo Stock Exchange Securities Listing Regulations.

Decision and Details
ItemDetails
Matter CoveredDelisting of our shares
Decision-Making BodyExtraordinary General Meeting of Shareholders
Decision Date25 May 2026
Implementation Date11 June 2026 (scheduled; delisting from the Tokyo Stock Exchange Standard Market)
ReasonThe proposal concerning the share consolidation was approved as originally proposed, resulting in the shares meeting the delisting criteria stipulated in the Tokyo Stock Exchange Securities Listing Regulations.
Governing RuleDelisting criteria stipulated in the Tokyo Stock Exchange Securities Listing Regulations
Related previous disclosuresNotice Concerning the Approval Resolution on the Share Consolidation, Abolition of the Provisions on the Number of Shares per Unit and Partial Amendments to the Articles of Incorporation, dated 25 May 2026
Future plansThe shares will be delisted from the Tokyo Stock Exchange Standard Market effective 11 June 2026.
Items this document does not state (4)
Period CoveredAmountQuantity / scaleImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The proposal for a share consolidation was approved at the extraordinary general meeting of shareholders held on 25 May 2026, resulting in the shares meeting the delisting criteria stipulated in the Tokyo Stock Exchange Securities Listing Regulations.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of the Delisting of Our Shares | KAINOS Laboratories,Inc. (4556) timely disclosure | Komori